Skip to main content

KURA

Stock
Health Care
Biotechnology

Performance overview

KURA Price
Price Chart

Forward-looking statistics

Beta
1.38
Risk
64.36%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

Company info

SectorHealth Care
IndustryBiotechnology
Employees144
Market cap$1.7B

Fundamentals

Enterprise value-$139.3M
Revenue$68.0M
Revenue per employee
Profit margin-267.52%
Debt to equity5.31

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$2.09
Dividend per share
Revenue per share$0.78
Avg trading volume (30 day)$8M
Avg trading volume (10 day)$9M
Put-call ratio

Macro factor sensitivity

Growth+1.2
Credit+4.6
Liquidity-0.4
Inflation-1.7
Commodities-0.7
Interest Rates-2.7

Valuation

Dividend yield0.00%
PEG Ratio-2.19
Price to sales7.46
P/E Ratio-2.19
Enterprise Value to Revenue-2.05
Price to book1.30

Upcoming events

Next earnings dayMay 2, 2025
Next dividend day
Ex. dividend day

News

Is the Options Market Predicting a Spike in Kura Oncology Stock?

Investors need to pay close attention to KURA stock based on the movements in the options market lately.

Zacks Investment Research (June 12, 2025)
Kura Oncology Cancer Study Hits Primary Goal, Lays Out Plans For Phase 3 Studies

Kura Oncology, Inc. KURA and Kyowa Kirin Co., Ltd released topline results from a Phase 2 registration-directed trial of ziftomenib for relapsed/refractory (R/R) NPM1-mutant (NPM1-m) acute myeloid leukemia (AML).

Benzinga (February 6, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free